U.S. Markets closed

Laurus Labs Limited (LAURUSLABS.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
482.05-1.95 (-0.40%)
At close: 3:30PM IST

Laurus Labs Limited

Serene Chambers
2nd Floor Road No. 7 Banjara Hills
Hyderabad 500034
91 40 3980 4333

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees4,808

Key Executives

NameTitlePayExercisedYear Born
Dr. Satyanarayana Chava M.Sc., Ph.D.CEO & Whole Time Director178.57MN/A1961
Mr. Vantaram Venkata Ravi Kumar F.C.M.A., DIS, Dip in Mgmt.CFO & Whole-Time Director43.98MN/A1965
Mr. Narasimha Rao ChavaSr. VP of HRN/AN/A1968
Mr. Srinivasa Rao Suryadevara M.Sc., B.ScSr. VP of ManufacturingN/AN/A1963
Dr. Vaidyanathan Narayanaswamy IyerSr. VPN/AN/A1963
Mr. Chagarlamudi Sita RamaiahSr. VP of Fin.N/AN/A1973
Mr. Dammalapati Venkata Lakshmi Narasimha RaoSr. VP of SynthesisN/AN/A1969
Dr. Prafulla Kumar Nandi Ph.D.Sr. VP of Global Regulatory AffairsN/AN/A1969
Mr. Krishna Chaitanya ChavaExec. VP and Head of Synthesis & IngredientsN/AN/A1990
Mr. Gogireddy Venkateswar ReddyAsst. VP of Legal & Secretarial, Compliance Officer & Company Sec.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.


Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it offers chemistry, IP development, business support, and related services to the pharmaceutical community. Laurus Labs has agreements with Unitaid and the Clinton Health Access Initiative, Inc. to enhance the development, commercialization, and registration of second- and third-line HIV treatment darunavir boosted with ritonavir for children. The company was incorporated in 2005 and is based in Hyderabad, India.

Corporate Governance

Laurus Labs Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.